Stemline Therapeutics’ SL-401 Phase 2 BPDCN Trial Results To Be Delivered Via Oral Presentation at the American Society of ...
NEW YORK, June 03, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm (BPDCN) will be the subject of an oral presentation at the 2016 …